Cargando…

Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors

Brain GABA(Α) receptors are ionotropic receptors belonging to the class of Cys-loop receptors and are important drug targets for the treatment of anxiety and sleep disorders. By screening a compound library (2,112 compounds) at recombinant human α(4)β(1)δ GABA(Α) receptors heterologously expressed i...

Descripción completa

Detalles Bibliográficos
Autores principales: Falk-Petersen, Christina Birkedahl, Tsonkov, Tsonko M., Nielsen, Malene Sofie, Harpsøe, Kasper, Bundgaard, Christoffer, Frølund, Bente, Kristiansen, Uffe, Gloriam, David E., Wellendorph, Petrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308271/
https://www.ncbi.nlm.nih.gov/pubmed/32572053
http://dx.doi.org/10.1038/s41598-020-66821-0
_version_ 1783548954677346304
author Falk-Petersen, Christina Birkedahl
Tsonkov, Tsonko M.
Nielsen, Malene Sofie
Harpsøe, Kasper
Bundgaard, Christoffer
Frølund, Bente
Kristiansen, Uffe
Gloriam, David E.
Wellendorph, Petrine
author_facet Falk-Petersen, Christina Birkedahl
Tsonkov, Tsonko M.
Nielsen, Malene Sofie
Harpsøe, Kasper
Bundgaard, Christoffer
Frølund, Bente
Kristiansen, Uffe
Gloriam, David E.
Wellendorph, Petrine
author_sort Falk-Petersen, Christina Birkedahl
collection PubMed
description Brain GABA(Α) receptors are ionotropic receptors belonging to the class of Cys-loop receptors and are important drug targets for the treatment of anxiety and sleep disorders. By screening a compound library (2,112 compounds) at recombinant human α(4)β(1)δ GABA(Α) receptors heterologously expressed in a HEK cell line, we identified a scaffold of spirocyclic compounds with nanomolar antagonist activity at GABA(Α) receptors. The initial screening hit 2027 (IC(50) of 1.03 μM) was used for analogue search resulting in 018 (IC(50) of 0.088 μM). 018 was most potent at α(3,4,5)-subunit containing receptors, thus showing preference for forebrain-expressed extrasynaptic receptors. Schild analysis of 018 at recombinant human α(4)β(1)δ receptors and displacement of [(3)H]muscimol binding in rat cortical homogenate independently confirmed a competitive profile. The antagonist profile of 018 was further validated by whole-cell patch-clamp electrophysiology, where kinetic studies revealed a slow dissociation rate and a shallow hill slope was observed. Membrane permeability studies showed that 2027 and 018 do not cross membranes, thus making the compounds less attractive for studying central GABA(Α) receptors effects, but conversely more attractive as tool compounds in relation to emerging peripheral GABA(Α) receptor-mediated effects of GABA e.g. in the immune system.
format Online
Article
Text
id pubmed-7308271
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73082712020-06-23 Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors Falk-Petersen, Christina Birkedahl Tsonkov, Tsonko M. Nielsen, Malene Sofie Harpsøe, Kasper Bundgaard, Christoffer Frølund, Bente Kristiansen, Uffe Gloriam, David E. Wellendorph, Petrine Sci Rep Article Brain GABA(Α) receptors are ionotropic receptors belonging to the class of Cys-loop receptors and are important drug targets for the treatment of anxiety and sleep disorders. By screening a compound library (2,112 compounds) at recombinant human α(4)β(1)δ GABA(Α) receptors heterologously expressed in a HEK cell line, we identified a scaffold of spirocyclic compounds with nanomolar antagonist activity at GABA(Α) receptors. The initial screening hit 2027 (IC(50) of 1.03 μM) was used for analogue search resulting in 018 (IC(50) of 0.088 μM). 018 was most potent at α(3,4,5)-subunit containing receptors, thus showing preference for forebrain-expressed extrasynaptic receptors. Schild analysis of 018 at recombinant human α(4)β(1)δ receptors and displacement of [(3)H]muscimol binding in rat cortical homogenate independently confirmed a competitive profile. The antagonist profile of 018 was further validated by whole-cell patch-clamp electrophysiology, where kinetic studies revealed a slow dissociation rate and a shallow hill slope was observed. Membrane permeability studies showed that 2027 and 018 do not cross membranes, thus making the compounds less attractive for studying central GABA(Α) receptors effects, but conversely more attractive as tool compounds in relation to emerging peripheral GABA(Α) receptor-mediated effects of GABA e.g. in the immune system. Nature Publishing Group UK 2020-06-22 /pmc/articles/PMC7308271/ /pubmed/32572053 http://dx.doi.org/10.1038/s41598-020-66821-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Falk-Petersen, Christina Birkedahl
Tsonkov, Tsonko M.
Nielsen, Malene Sofie
Harpsøe, Kasper
Bundgaard, Christoffer
Frølund, Bente
Kristiansen, Uffe
Gloriam, David E.
Wellendorph, Petrine
Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors
title Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors
title_full Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors
title_fullStr Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors
title_full_unstemmed Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors
title_short Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA(A) receptors
title_sort discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic gaba(a) receptors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308271/
https://www.ncbi.nlm.nih.gov/pubmed/32572053
http://dx.doi.org/10.1038/s41598-020-66821-0
work_keys_str_mv AT falkpetersenchristinabirkedahl discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors
AT tsonkovtsonkom discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors
AT nielsenmalenesofie discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors
AT harpsøekasper discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors
AT bundgaardchristoffer discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors
AT frølundbente discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors
AT kristiansenuffe discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors
AT gloriamdavide discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors
AT wellendorphpetrine discoveryofanewclassoforthostericantagonistswithnanomolarpotencyatextrasynapticgabaareceptors